Alkermes Pharma Ireland Limited

Xeolas Pharmaceuticals Ltd.

Flak Pharma International, Ltd.

Maurice Joseph Anthony Clancy

Rajeev A Jain

Janet Elizabeth Codd

Gary G Liversidge

John G Devane

Jon Swanson

Robert Hontz

Damien Patrick Flynn

Dennis Mark McDaid

Kenneth Iain Cumming

H William Bosch

Stephen B Ruddy

Niels Peter Ryde

Kenneth Ian Cumming

The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.

Pediatric suspension formulation

Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.

Controlled-release nanoparticulate compositions

The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.

Glipizide compositions

Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.

Rapidly disintegrating solid oral dosage form

Growing community of inventors

Dublin, Ireland

Maurice Joseph Anthony Clancy